Patient recruitment and screening are underway in the LYNX-1 phase 3 registration study to investigate the safety and efficacy of Nyxol for night vision disturbances, Ocuphire Pharma announced in a press release.
One hundred sixty patients with night vision disturbances are expected to be enrolled in the randomized, double-masked, placebo-controlled trial, the release said. Participants will self-administer either Nyxol, a preservative-free eye drop formulation of phentolamine mesylate, or placebo in each eye daily for 14 days.
“Nyxol is currently the only product candidate we are aware
Uncategorized